Why the study?
Does in vivo platelet aggregation show circadian variation in atherosclerotic patients and healthy subjects?
Does in vivo platelet aggregation show circadian variation in atherosclerotic patients and healthy subjects?
Circulating platelet aggregates exhibit significant circadian variation, peaking at 6 a.m., which may have implications for the timing of antiplatelet therapy administration.
Does not support changing antiplatelet timing; leaves open whether morning platelet peaks warrant chronotherapy trials.
Acute coronary events are more likely to occur in the morning and it has recently been shown that platelet aggregability increases significantly then. To determine whether circulating platelet aggregates show such a circadian variation, we measured in vivo platelet aggregation in atherosclerotic patients and healthy subjects at three-hour intervals throughout a 24-hour period. We found a significant variation in circulating platelet aggregates, the highest being at 6 a.m. and the lowest at 9 a.m. We suggest that it may be important to consider the duration of action of anti-aggregating drugs and timing their administration with respect to circadian variation in circulating platelet aggregates.
No takes yet. Share an insight, caveat, or question.
Ündar et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: